Medovir (Aciclovir)

Aciclovir is a nucleoside analogue that, after activation by viral thymidine kinase, becomes a triphosphate that inhibits viral DNA polymerase. This blocks viral DNA chain elongation, preventing replication of herpes viruses and limiting disease progression.

The specific dose of Medovir is determined by the prescribing clinician based on the infection being treated, patient weight, renal function, and severity of disease. Dosing regimens are individualized and should follow the prescriber’s instructions.

Safety data for aciclovir in pregnancy and lactation are limited, and the product is classified as having an unknown pregnancy category. It should only be used when the potential benefit justifies any potential risk to the fetus or infant.

To order Medovir, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain where required) and import documentation.

Compared with oral agents such as valacyclovir or famciclovir, Medovir provides rapid, high‑level systemic exposure via intravenous infusion, which is advantageous for severe or disseminated infections. Oral antivirals are convenient for mild disease but may achieve lower plasma concentrations than IV aciclovir.

Medovir must be stored at 2‑8 °C in a refrigerator, protected from light, and must not be frozen or shaken. Prior to use, the solution should be inspected for particulate matter and used within the time frame recommended by the manufacturer after dilution.

Medovir is given by intravenous infusion. The product is typically diluted in an appropriate compatible fluid and infused over a period specified by the prescriber, often ranging from 30 minutes to several hours depending on the indication and patient tolerance.

Serious adverse events include nephrotoxicity, thrombocytopenia, severe allergic reactions such as anaphylaxis, seizures, and hepatic dysfunction. Patients should be monitored for changes in renal function, blood counts, liver enzymes, and any signs of hypersensitivity during therapy.

Medovir is contraindicated in patients with known hypersensitivity to aciclovir or any of the formulation components. Caution is advised for individuals with severe renal impairment, pregnant women when benefits do not outweigh risks, and patients receiving other nephrotoxic medications.